|
Out of the total 376 projects in the pharmaceutical sector, 181 have already been commissioned with 19 in preliminary stages, as part of Rs. 29,246 crore proposed investment made till date as part of Vibrant Gujarat Global Summit (VGGS) 2024, informed Dr. H G Koshia, Commissioner of the Gujarat Food & Drug Control Administration (FDCA) marking a significant milestone in Gujarat’s pharma infrastructure growth.
A further 153 projects are actively under implementation, indicating strong momentum in the sector.
According to the latest data released on July 29, 2025 by the Gujarat Food & Drug Control Administration (FDCA), a total of 376 Memorandums of Understanding (MoUs) or projects in the pharmaceutical sector have been signed since 2019, representing big increase in proposed investments.
"Only 23 projects were dropped, suggesting a high rate of conversion from MoU to execution, a sign of Gujarat’s investor-friendly environment and policy stability. The state’s pharma ecosystem, supported by world-class infrastructure and regulatory support, has become a magnet for both domestic and global investors," Dr. Koshia said.
Industry leaders echoed similar optimism, emphasizing Gujarat’s strengths in skilled manpower and an efficient single-window clearance system that simplifies project approvals. Industry experts stated that the rising investment in bulk drugs, Active Pharmaceutical Ingredients (APIs), biotechnology, and formulation units will further cement Gujarat’s dominance in the sector.
“The projects under VGGS 2024 are expected to not only increase Gujarat’s share in the global pharmaceutical supply chain but also generate thousands of direct and indirect employment opportunities, boosting the state’s economy post-pandemic. The VGGS continues to live up to its name, serving as a powerful platform for strategic partnerships and large-scale investments. The pharmaceutical sector's robust performance, both in terms of numbers and actual ground-level execution, reaffirms the state’s role as a cornerstone of India’s pharma and healthcare vision,” Dr. Koshia concluded.
|